Case Reports

Hyperthyroidism • myalgia • rapidly progressing paralysis • Dx?

Author and Disclosure Information

 

References

Our patient. Once our patient’s hypokalemia was corrected, she was successfully extubated. Despite appropriate medical therapy, her hyperthyroidism was poorly controlled. The endocrinologist believed that RIA was suboptimal for 3 reasons: 1) it might result in incomplete ablation, 2) it required a long treatment period to be effective, and 3) its prolonged course of treatment extended the time interval that the patient would be at risk for recurrent paralysis.

A surgeon was consulted for definitive treatment with thyroidectomy. Our patient’s medications were changed to propylthiouracil 150 mg every 8 hours and propranolol 10 mg twice a day until a euthyroid state was achieved and she could tolerate a general anesthetic without precipitating a thyroid storm. Two months later, she underwent total thyroidectomy without complication. Her postoperative course was normal.

THE TAKEAWAY

Thyrotoxic hypokalemic periodic paralysis is rare. Patients typically present with myalgia, cramping, and stiffness that progress to paralysis. Prompt electrolyte repletion is paramount for successful outcomes.1-5 Control of hyperthyroidism is the long-term goal.1-5 Definitive therapy can be achieved medically or surgically. Total thyroidectomy is a reasonable treatment option for medically refractory hyperthyroidism or when RIA is contraindicated. Long-term prognosis is excellent.

Pages

Recommended Reading

Radioactive iodine may boost survival in papillary thyroid cancer
MDedge Family Medicine
Bariatric surgery an opportunity to screen for endometrial cancer
MDedge Family Medicine
Preeclampsia and swelling
MDedge Family Medicine
Bilateral hand cramping and weakness • broad fingers • coarse facial features • Dx?
MDedge Family Medicine
North America has highest rate of obesity-related cancers
MDedge Family Medicine
FDA approves newborn screening test for SCID
MDedge Family Medicine
Bisphosphonates may protect against endometrial cancer
MDedge Family Medicine
FDA approves PARP-inhibitor for ovarian cancer
MDedge Family Medicine
International study characterizes male breast cancer
MDedge Family Medicine
Annular plaques on the back and flanks
MDedge Family Medicine

Related Articles